What Amorchem does

Amorchem is a Montreal, Canada-based venture capital fund founded in 2011 that focuses on creating and backing promising life science companies. The firm operates with a small team of 1-10 employees, consistent with a specialist life sciences venture model where investment selection relies on deep domain expertise and active company-creation rather than high-volume deal flow.

The fund's core activity is sourcing, building, and financing early-stage life science ventures in the Quebec/Canadian ecosystem. Its business model follows the standard venture fund structure: it raises capital from limited partners, deploys that capital into portfolio companies, and earns returns through a combination of management fees on assets under management and carried interest on successful exits. In November 2018, the firm secured a $50,000,000 financing round with VCCI as lead investor, providing material dry powder for continued investment activity. The leadership team includes Founder & Partner Elizabeth Douville and CFO & Partner Maxime Pesant, whose domain and financial roles anchor fund operations.

No specific portfolio companies, AUM growth, performance metrics, or recent transaction activity are disclosed in the available input material, limiting forward visibility into investment pacing, exit realization, or fee revenue trends beyond the inferred management-fee economics on the single observed fund close.

Name

Amorchem

Website

https://amorchem.com

Company type

Private

Founded year

2011

Headcount range

1–10 employees

Short description

Amorchem is a Montreal-based venture capital fund founded in 2011 that creates and invests in early-stage life science companies, operating with a small specialized team of 1-10 employees.

Ownership category

akta.pro rank

Product category

Life Sciences Venture Capital

NAICS

Portfolio Management and Investment Advice (52394)

SIC

Investment Advice (6282)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

Keywords

• Venture capital
• Life sciences investment
• Biotech funding
• Early-stage pharma
• Healthcare venture

Headquarters

HQ city

Montréal

HQ country

Canada

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Others

Core offering

Amorchem is a venture capital fund that invests in and builds early-stage life sciences companies. The firm deploys committed capital into biotech, pharmaceutical, and medical-technology ventures primarily sourced from the Montreal research ecosystem. It operates as a hands-on, founder-led investment partner, providing both capital and operational support to portfolio companies from inception through value-inflection milestones.

Differentiator

Problem solved

Functional benefit

Products and services

• Amorchem Life Sciences Venture Fund Venture capital fund (with a CAD $50M commitment from the Venture Capital Catalyst Initiative raised on 2018-11-05) that invests in early-stage life sciences companies, providing capital, operating support, and partner-led company-building to biotech and health-technology ventures.

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves2 records

Expansion highlights2 records

Direct peers

• Lumira Ventures: Canadian healthcare and life-sciences venture capital firm investing across biotech and digital health; highly comparable to Amorchem in mandate, regional presence, and fund size.
• Genesys Capital: Toronto-based Canadian life-sciences venture capital firm that builds and backs emerging health companies; directly comparable to Amorchem in sector focus and early-stage strategy.
• TVM Life Science Ventures: Montreal-based life-sciences venture capital firm focused on early-stage therapeutics; closely comparable to Amorchem in geography, sector focus (Canadian biotech), and company-creation thesis.

Broad incumbents

• Versant Ventures: Large, established North American healthcare and biotech venture capital firm; comparable sector focus but materially larger fund sizes and broader stage remit than Amorchem.
• OrbiMed Advisors: Global healthcare-dedicated investment firm spanning venture, growth, credit, and public equities; comparable life-sciences focus but operates at vastly greater scale than Amorchem.
• Frazier Life Sciences: US-based life-sciences-focused venture capital firm investing across biopharma; comparable in vertical specialization but with larger capital bases than Amorchem.
• SR One (GSK): Translational biotech venture firm originally linked to GSK, investing in early-stage therapeutics and platforms; comparable specialization but corporate CVC-style backing contrasts with Amorchem's independent model.
• Domain Associates: Healthcare-focused growth and venture capital firm investing across biotech and medical devices; comparable vertical scope to Amorchem but with later-stage bias.

Emerging players

• 5AM Ventures: US biotech early-stage venture firm focused on company creation from academic science; comparable founding thesis to Amorchem in building companies from research-stage assets.

Regional players

• BDC Capital (Health Venture): Canadian Crown corporation venture arm with a dedicated healthcare/life-sciences fund supporting early-stage Quebec and Canadian biotech; comparable regional footprint and stage focus to Amorchem.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks10 records

Key highlights10 records

Customer concentration

• Xx.com/amorchem

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments7 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amorchem